Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 6/20 | 0.36 |
| ▸ | RXRA | P19793 | 1/20 | 0.34 |
| ▸ | RXRB | P28702 | 1/20 | 0.34 |
| ▸ | TOP2A | P11388 | 1/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.32 |
| ▸ | METAP2 | P50579 | 1/20 | 0.32 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16268477 | 0.83 | HIPK2 (0.33) | POLBMAPTMETAP2 | |
| SCHEMBL16268476 | 0.83 | HIPK2 (0.33) | POLBMAPTMETAP2 | |
| SCHEMBL20128566 | 0.81 | NPC1 (0.43) | RAB9APOLBNPC1GAARXFP1 | |
| SCHEMBL14134198 | 0.80 | MAPT (0.48) | RAB9APOLBNPC1GAARXFP1 | |
| SCHEMBL22906702 | 0.80 | NPC1 (0.43) | RAB9APOLBNPC1GAARXFP1 | |
| SCHEMBL29547590 | 0.80 | MAPT (0.48) | RAB9APOLBNPC1GAARXFP1 | |
| SCHEMBL16268180 | 0.79 | GABRG2 (0.38) | MAPT | |
| SCHEMBL27097256 | 0.79 | NPC1 (0.41) | RAB9APOLBNPC1GAARXFP1 | |
| SCHEMBL20128557 | 0.77 | CYP11B2 (0.47) | METAP2 | |
| SCHEMBL13465254 | 0.76 | MAPT (0.56) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160115162-A1 | Radiosynthesis of Tau Radiopharmaceuticals | THE GENERAL HOSPITAL CORPORATION | 2016-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160115162-A1 | Radiosynthesis of Tau Radiopharmaceuticals | HTR7, MAPT, TSN | RAB9A 1795/4885POLB 104/4885NPC1 2012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.